医学
氯氮平
帕利哌酮
部分激动剂
精神分裂症(面向对象编程)
药理学
鲁拉西酮
抗精神病药
内科学
精神科
受体
敌手
作者
Filipa Viegas,Tiago Miguel Ferreira,Claudia M. Campos
出处
期刊:Neuropsychiatric Disease and Treatment
[Dove Medical Press]
日期:2022-06-01
卷期号:Volume 18: 1145-1149
被引量:3
摘要
Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia. It presents distinct pharmacodynamic properties, such as D3/D2 partial agonism, preferential binding to D3 receptors, antagonism at the serotonin 5-HT2A and 5-HT2B receptors, partial agonism at 5-HT1A receptors, and low affinity to other receptors (including noradrenergic, histaminergic, and cholinergic). It has demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia with a safe side effect and metabolic profile.Here, we describe one clinical case of a patient that benefited from an add-on of cariprazine to a regimen of clozapine; and two clinical cases of patients that benefited from the switch from clozapine and paliperidone long-acting injectable to cariprazine.Those cases illustrate how cariprazine can be used in patients with schizophrenia in the treatment of both positive and negative symptoms, and when aiming to ameliorate the metabolic burden associated with other treatments. However, further studies are needed to consubstantiate those findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI